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Abstract
p53, can regulate cell apoptosis in both transcription-dependent and -independent manners. The transcription-
independent pathway was demonstrated by the translocation of p53 to mitochondria. Our study showed that p53
mitochondrial translocation was found in mitomycin C (MMC)–treated HepG2. The p53 C-terminal domain is clus-
tered with potential nuclear leading sequences and showed strong electrostatic ion-ion interactions with cardiolipin,
phosphatidylglycerol and phosphatidic acid in vitro. Disruption of cardiolipin biosynthesis by phosphatidylglycero-
phosphate synthase (PGS) or CDP-diacylglycerol synthase 2 (CDS-2) short hairpin RNA (shRNA) transfection elimi-
nated the MMC-induced translocation of mitochondrial p53. The elimination of mitochondrial p53 translocation also
reduced Bcl-xL and Bcl-2 mitochondrial distribution. In HEK 293T models with saturated p53 expression, the mito-
chondrial partition of p53, Bcl-xL, and Bcl-2 obviously decreased in their PGS shRNA- or CDS-2 shRNA-expressing
stable clones. In p53-null H1299 models, both the mitochondrial partitions of Bcl-xL and Bcl-2 were strongly reduced
in relation to the HEK 293T models. The Bcl-xL mitochondrial partition was elevated in H1299 models expressing
pCEP4-p53wt suggesting the direct carrier role of p53 in transporting Bcl-xL to the mitochondria. We also found
that the cytosolic pool of Bcl-xL and Bcl-2 remained unaffected in the low-dose MMC treatment but decreased in
the high-doseMMCtreatment. Thecytosolic pool ofBcl-2 andBcl-xL directly regulated their amounts in p53-dependent
mitochondrial distribution. In the low-dose MMC treatment, the increased mitochondrial p53, Bcl-xL, and Bcl-2 could
attenuate apoptosis. However, in the high-dose MMC treatment, only the p53 translocated to the mitochondria and
resulted in apoptosis progression.On the basis of this study,we thoughtmitochondrial p53might regulate apoptosis in
a biphasic manner.
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Introduction
p53 was the first tumor suppressor gene identified in 1979. The p53
protein consists of 393 amino acids, and its structure is subdivided into
anN-terminal transactivation domain, a central DNA-binding domain,
and a C-terminal domain [1–3]. Once activated, p53 is phosphorylated
and it escapes fromubiquitin degradation. Activated p53 showsmultiple
functions including cell cycle regulation [2], DNA repair, and apoptosis
[4–7]. p53-Associated apoptotic regulation can be achieved in a tran-
scription-dependent or -independent manner. p53-Dependent tran-
scription of mitochondria-anchored proapoptotic products [5,6] and
p53-inducible genes [4,7] disrupts mitochondrial integrity and causes
cytochrome c release. The transcription-independent apoptotic signal
is induced by p53 protein-protein interactions in the mitochondria
Abbreviations: 293T-PGS shRNA, PGS shRNA-transfected 293T cell; CDS-2, CDP-
diacylglycerol synthase 2; CLS, cardiolipin synthase; Cox I, cytochrome c oxidase sub-
unit I; HepG2-PGS shRNA, PGS shRNA-transfectedHepG2 cell;MMC,mitomycin C;
NLS, nuclear leading sequence; PGS, phosphatidylglycerophosphate synthase; shRNA,
short hairpin RNA
Address all correspondence to: Jaw-Jou Kang, PhD, Institute of Toxicology, College of
Medicine, National Taiwan University, No, 1 Jen-Ai Rd, Section 1, Taipei, Taiwan.
E-mail: jjkang@ntu.edu.tw
1This article refers to supplementarymaterials, which are designated by FiguresW1 toW3
and are available online at www.neoplasia.com.
Received 2 September 2009; Revised 19 November 2009; Accepted 23 November 2009
Copyright © 2010 Neoplasia Press, Inc. All rights reserved 1522-8002/10/$25.00
DOI 10.1593/neo.91500
www.neoplasia.com
Volume 12 Number 2 February 2010 pp. 150–160 150
[8,9]. Candidate proteins interacting with p53 in themitochondria were
identified one by one [10–14]. However, the mechanism by which p53
is translocated to mitochondria is still unknown.
Cardiolipin (1,3-bis (19,29-diacyl-39-phosphoryl-sn-glycerol)-sn-
glycerol) is amitochondria-restricted, anionic, asymmetric phospholipid.
Cardiolipin is the major component of mitochondria phospholipids
(comprising approximately 8%-15%) of both the outer and the inner
membranes [15,16]. Cardiolipin biosynthesis is regulated by the CDP-
diacylglycerol synthase (CDS) that converts phosphatidic acid to CDP-
diacylglycerol. Phosphatidylglycerophosphate synthase (PGS, EC
2.7.8.5) catalyzes the formation of phosphatidylglycerophosphate
from CDP-diacylglycerol and glycerol-3-phosphate. Phosphatidylgly-
cerophosphate is then dephosphorylated to phosphatidylglycerol
by phosphatidylglycerophosphate phosphatase. Then, cardiolipin
synthase (CLS) converts phosphatidylglycerol to cardiolipin through
condensation with CDP-diacylglycerol [15–17]. Human CLS was
identified and cloned in 2006 [18]. The functional mutation of PGS
and CLS was demonstrated to cause cardiolipin depletion. Cardiolipin-
depleted cells often show electron transport inhibition [19], changes in
ion permeability and membrane integrity [19], a decrease in protein
importation [20], and collapse of mitochondria membrane potential
[20,21]. These findings suggest the crucial physiological and pathologi-
cal position of cardiolipin in the mitochondria.
In the present study, the mitochondrial translocation of p53 was in-
vestigated inmitomycin C (MMC)–treated cells. We found that cardio-
lipin tightly bound to the C-terminal region of p53 protein in vitro.
Down-regulation of PGS and CDS protein expressions diminished
the content of p53 translocation to the mitochondria, suggesting that
a specific p53-cardiolipin interaction is an important step in triggering
its mitochondrial distribution.Moreover, the p53 protein was also dem-
onstrated to interact with Bcl-xL [10,11], and the p53–Bcl-xL protein
interaction might lead to Bcl-xL mitochondrial translocation and cell
death regulation.
Materials and Methods
Cell Culture
The hepatocarcinoma cell line HepG2, the adenocarcinoma cell line
A549, the HEK 293T cells with endogenous wild-type p53, and the
p53-null H1299 cells were purchased from American Type Culture
Collection (ATCC; Manassas, VA). All cell lines were maintained in
Dulbecco’s modified Eagle medium with 10% heat-inactivated fetal
bovine serum in a humidified atmosphere of 5% CO2 in a 37°C incu-
bator. The CDP-diacylglycerol synthase 2 (CDS-2) short hairpin RNA
(shRNA)- and PGS shRNA-expressing stable clones were selected from
transfected HEK 293T and H1299 cells, respectively, by the addition
of 1 μg/ml puromycin.
Transfection
Transfection was performed by using PolyJet in vitro DNA transfec-
tion reagent (SignaGen Laboratory, Gaithersburg,MD) at 24 hours after
seeding. CDP-diacylglycerol synthase-2 (CDS-2, TRCN0000035859)
and PGS (TRCN0000045342) shRNA pLKO.1-puro constructs were
purchased from the National RNAi Core Facility (Academia Sinica,
Taipei, Taiwan). The pCEP4 vector and pCEP4-p53wt were kindly
provided by Dr. Tzeng SL (Chung Shan Medical University). Briefly,
1 to 5 μg of shRNA or plasmid and PolyJet reagent were respectively
diluted within an incomplete Dulbecco’s modified Eagle medium,
then mixed vigorously and incubated at room temperature. Twenty min-
utes later, themixture was layered on serum-free culturemedium.Cells
were transfected for at least 6 hours.
Isolation and Purification of Mitochondria
Treated cells were incubated in hypotonic buffer for 10 minutes, fol-
lowed by a homogenizing procedure for 10 seconds, five to six times.
The cell debris was separated by the first centrifugation at 1200g for
10 minutes. The supernatant was transferred to tubes, and the heavy
membrane pellet enriched in the mitochondria was isolated by the
second centrifugation at 10,000g for 10 minutes. The mitochondria-
enriched fraction was layered on a discontinuous sucrose gradient
(1.0 M and 1.5 M sucrose prepared in 5 mM EDTA, 10 mM Tris-
HCl, pH 7.4). Finally, mitochondria were purified from the 1.0/1.5 M
interface after a third centrifugation.
Alkali Extraction
For alkali extraction [22], pure mitochondria were incubated with
100 mM Na2CO3 (pH 11.5) for 10 minutes on ice. The pellet sepa-
rated by centrifugation at 12,000g was used as the integral membrane
fraction. The supernatant was denoted the soluble fraction.
Western Blot Analysis
Intact cell lysates and mitochondria lysates were prepared using RIPA
buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EGTA,
1 mMNaF, 1 mMNa3VO4, and proteinase inhibitor cocktail) contain-
ing 1% Nonidet P-40 or 1% dodecymaltoside, respectively. Protein
concentration was determined by the Bradford method (Bio-Rad,
CA). Adequate lysates were mixed well with sodium dodecylsulfate–
polyacrylamide gel electrophoresis loading buffer and separated by
10% or 12% sodium dodecylsulfate–polyacrylamide gel electrophore-
sis. The separated proteins were electroblotted onto the polyvinylidene
difluoride (PVDF) sheets. For immunodetection, the PVDF mem-
brane was blocked in nonfat milk and incubated in Tris-buffered saline
with Tween-20 with antibodies specific to p53 (05-224; Upstate Biotech,
Lake Placid, NY), Mdm-2 (clone SMP14; NeoMarker, Fremont, CA),
proliferating cell nuclear antigen (clone PC10; NeoMarker), Bax (clone
2D2; NeoMarker), Core II (A11143; Molecular Probes, Carlsbad, CA),
PGS (H00009489; Abnova, Taipei, Taiwan), CDS-2 (H00008760;
Abnova), Bcl-2 (sc-509; Santa Cruz Biotechnology, Santa Cruz, CA),
Bcl-xL (clone 2H12; eBiosciences, San Diego, CA), and β-actin (Sigma,
Saint Louis, MO). For chemiluminescent detection, PVDF blots were
incubated with horseradish peroxidase–conjugated secondary antibody
(1:5000 in Tris-buffered saline with Tween-20) for 2 hours at room
temperature, followed by enhanced chemiluminescence detection, ac-
cording to the manufacturer’s protocol (Millipore, Billerica, MA).
Confocal Microscopy
For immunofluorescent studies, cells were seeded on cover glasses.
Treated cells were fixed and permeablized with ice-cold MeOH. The
first antibodies’ reactions specific to p53 (sc-6243; Santa Cruz Bio-
technology), Histone H1 (sc-8030; Santa Cruz Biotechnology), cyto-
chrome c oxidase subunit I (Cox I, A-6403; Molecular Probes) were
performed overnight at 4°C (1: 200 dilution in phosphate-buffered
saline with Tween). Conjugation of the secondary antibodies with fluo-
rescein isothiocyanate or tetramethyl rhodamine isothiocyanate reac-
tion (Santa Cruz Biotechnology) was performed at 25°C for 2 hours.
Cells were observed under a Leica confocal laser microscope (Leica
Microsystems, Wetzler, Germany) with excitation and emission at
488 and 543 nm, respectively.
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Recombinant Fusion Protein Expression
pGEX-1 plasmids encoded with the sequences of full-length human
p53, or p53 deletions or mutants, were transformed into Escherichia coli
BL21 using calcium chloride. Recombinant fusion protein expression
was performed by 0.25 mM isopropyl β-D-1-thiogalactopyranoside in-
duction for 3 hours at 30°C [23]. Cells were lysed by sonication
in phosphate-buffered saline (PBS) containing 1 mM dithiothreitol,
1 mM phenylmethylsulphonyl fluoride, 0.2 mM EDTA. After centri-
fugation, the glutathione S-transferase fusion protein in the supernatant
was bound with 50% (vol./vol.) glutathione-agarose beads. The fusion
protein was eluted by 50 mM Tris buffer (pH 7.5) with 50 mM re-
duced glutathione.
Lipid-Binding Assay
The interaction of recombinant p53 fusion protein and phospholipids
was evaluated in vitro [22]. Fifty microliters per well of phospholipids
(100 μg/ml dissolved in EtOH) was coated onto 96-well plates by
evaporation at room temperature. The coated plates were tested within
24 hours. Target proteins diluted in phosphate-buffered saline with
Tween (1-10 μg/ml) were incubated within microwells at 25°C for
2 hours. The specific protein-lipid interaction was detected by immuno-
colorimetric optical density of 3,3′,5,5′-tetramethylbenzidine at
450 nm.
Apoptotic Index Analysis
Cells seeded in six-well plates were treated as indicated. To identify and
quantify DNA content, cells were trypsinized, fixed overnight in 70%
ethanol, and then resuspended in PBS containing RNase A (10 μg/ml)
and propidium iodide (25 μg/ml). Apoptotic cells with the sub-G1 peak
localized below the G0/G1 peak were identified by flow cytometry with
FL2 filter [24].
Statistical Analysis
All data were expressed as mean ± SEM from at least three inde-
pendent experiments. Statistical analysis was carried out by analysis of
variance (SPSS 12.0, Sinter Information Group, Taipei, Taiwan), and
P < .05 was considered significantly different.
Results
The Activated p53 Protein Was Found in Both Nuclear and
Mitochondrial Fractions
The DNA damage agent MMC can induce endogenous p53 protein
accumulation in both dose- and time-dependent manners in HepG2
cells. Interestingly, the activated p53 protein was also found in the
purified mitochondria fraction (Figure 1, A and B). The mitochondrial
marker, Core II, and the nuclear protein, proliferating cell nuclear an-
tigen, were used for quality control of mitochondria fractionation
(Figure 1A). MMC (5-10 μg/ml) treatment for 6 hours caused six- to
eight-fold increases in mitochondrial p53 translocation (Figure 1A).
In the time-dependent studies, 5 μg/ml MMC incubation for 3, 6,
and 12 hours caused 4.8-, 6.7-, and 12.7-fold increases inmitochondrial
p53 translocation (Figure 1B). The translocation of p53 protein tomito-
chondria was also observed by immunofluorescent staining. In intact
A549 cells, the colocalization of p53 with nuclear histone H1 or mito-
chondria Cox I is shown in merged images (Figure 1C). Mitochondrial
p53 translocation was also observed in p53-overexpressing H1299 cells
(data not shown).
Mitochondrial p53 Was Displayed in Both the
Membrane-Bound Form and Free Soluble Form
Unlike the membrane-integral Cox I protein, the mitochondrial p53
could be fully extracted by 100 mM alkali Na2CO3 (pH 11.5), suggest-
ing thatmitochondrial p53 retained its soluble characteristic (Figure 2A).
However, in 1% dodecymaltoside detergent extraction, mitochondrial
p53 was more resistant than the Cox I protein and was detected in both
the soluble supernatant fraction (soluble form p53) and the insoluble
pellet fraction (membrane-bound p53; Figure 2B).
Interaction of p53 with Cardiolipin through Its
C-terminal Domain
Thep53 protein-phospholipid interactionwas evaluated by an in vitro
lipid-binding assay [22]. The recombinant p53-GST fusion protein
showed high lipid-binding properties with phosphatidylserine, phos-
phatidylglycerol, cardiolipin, and phosphatidic acid but showed lower
lipid-binding properties to phosphatidylcholine, phosphatidylethanol-
amine, phosphatidylinositol, cholesterol, and sphingomyelin (Fig-
ure 2C ). Both phosphatidic acid and phosphatidylglycerol were
anionic and were precursors in cardiolipin biosynthesis [15–17]. The
specific protein-lipid interactions were not found for GST protein itself
(Figure 2D).
Subsequently, the cardiolipin-binding activities of recombinantmutant
p53 protein (R175H), the N-terminal transactivation domain (p53-
1∼100), the DNA binding domain (p53-1∼318 and p53-100∼318)
and the C-terminal domain (p53-319∼393) were tested. The p53
C-terminal domain and R175H mutant showed strong cardiolipin-
binding activities. The p53 fragments containing 100 to 318 poly-
peptides showed mild cardiolipin-binding activity. However, the
N-terminal domain was irrelevant to p53-cardiolipin interaction
(Figure 2D).
To determine if cardiolipin and cardiolipin precursors function as a
carrier that transports p53 to the mitochondria, two key enzymes, PGS
and CDS, that are implicated in cardiolipin biosynthesis were studied.
Two CDS isoforms were identified in humans. CDS-1 is expressed in
the retina and is implicated in phototransduction. CDS-2 has a wide-
spread tissue distribution [25]. Therefore, CDS-2 was selected for fur-
ther studies.
Down-regulation of PGS Expression Decreased Cellular p53
Translocation to the Mitochondria
The efficacy of PGS shRNA constructs was screened by dose-
dependent transient transfection. The PGS shRNA construct (5 μg
of plasmids/6-cm transfection) caused 90% suppression of PGS protein
expression (Figure 3A) and decreased in cellular cardiolipin level
(Figure W1). In the whole lysate analysis, MMC induced p53 and
PGS expression in nontransfected control, vector control, and PGS
shRNA-transfected HepG2 cells (HepG2-PGS shRNA). MMC-
induced PGS expression might overwhelm the RNA interfering effect
of the shRNA construct. Contents of the p53 translocation to the mito-
chondrial fraction showed no significant differences among nontrans-
fected control, vector control, and HepG2-PGS shRNA (Figure 3B).
To resolve the RNA interfering problem, the p53 transactivation in-
hibitor, pifithrin-α (20 μM), was used for pretreatment and coincuba-
tion withMMC. Pifithrin-α inhibited transactivation of p53-responsive
gene expression, including Mdm-2 and PGS, but was irrelevant to p53
accumulation in whole lysate (Figure 3C) and p53 mitochondrial trans-
location (Figure 3D). Therefore, in the very condition, pifithrin-α pre-
treatment is necessary to work against the PGS expression induced
152 p53 Binding with Anionic Phospholipids Li et al. Neoplasia Vol. 12, No. 2, 2010
by MMC treatment and make sure the successful knockdown of
PGS protein. In Figure 3E , the p53 mitochondrial translocation re-
duced in the MMC-treated HepG2-PGS shRNA cell with pifithrin-α
pretreatment, but the reduction would not take place without the
pifithrin-α pretreatment. Therefore, we concluded that the decrease
in mitochondrial p53 resulted directly from PGS protein knockdown
rather than pifithrin-α.
Down-regulation of CDS-2 Expression Decreased Cellular
p53 Translocation to the Mitochondria
Dose-dependent transient transfection studies showed that theCDS-2
shRNA construct (5 μg of plasmids/6-cm transfection) caused 80%
suppression of CDS-2 protein expression (Figure 4A) and decreased cel-
lular cardiolipin level (Figure W1). In the whole lysate analysis, MMC
induced p53 accumulation in nontransfected control, vector control, and
HepG2–CDS-2 shRNA cells. The content of p53 translocated to the
mitochondria decreased in HepG2–CDS-2 shRNA cells (Figure 4B).
These results showed that disruption of cardiolipin biosynthesis dimin-
ished the content of mitochondrial p53 translocation, suggesting the
critical role of cardiolipin in p53 translocation to the mitochondria.
Decreased Mitochondrial p53 Content Enhanced
MMC-Induced Cell Death
The effects ofmitochondrial p53 content on cell death were evaluated
by the sub-G1 DNA formation. BeforeMMC treatment, the cell viabil-
ities (Figure 5A) and resting caspase 3 activities (data not shown) were
without significant changes among HepG2–wild-type, HepG2-PGS
shRNA, andHepG2-CDS shRNA cells.MMC (5-20 μg/ml) treatment
increased the sub-G1 DNA population in a dose-dependent manner.
MMC-induced apoptotic index remained unaffected by pifithrin-α
Figure 1. Activated p53 proteinwas found in both nuclear andmitochondrial fractions.Western blots showed thatMMC treatments induced
p53 accumulation in HepG2whole-cell lysate andmitochondrial lysate in both dose-dependent (A) and time-dependentmanners (B). In dose-
dependent studies, 5 and 10 μg/ml MMC was treated for 6 hours. In the time-dependent studies, 5 μg/ml MMC was treated for 3, 6, and
12 hours. The core II protein was used as a mitochondrial internal control. The nuclear PCNA protein was used to identify the fractionation
quality. The contents of mitochondrial p53 translocation were analyzed by densitometry. *P < .05, **P < .01, and ***P < .001, indicate
statistical significance. (C) Immunofluorescent images showed the endogenous p53 was colocalized with nuclear histone H1 (left panel)
and mitochondrial Cox I (right panel) in intact A549 cells.
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(20 μM) pretreatment (Figure 5A). In HepG2–CDS-2 shRNA and
HepG2-PGS shRNA cells with pifithrin-α pretreatment, 5 to 10 μg/ml
MMC treatments not only decreased mitochondrial p53 translocation
content but also enhanced the apoptotic index, which showed an increase
in sub-G1 DNA fraction. However, in HepG2-PGS shRNA cell without
pifithrin-α pretreatment, MMC-induced apoptotic indexes were without
significant changes compared withMMC-treated HepG2–wild-type cell.
In high-dose (20 μg/ml) MMC treatment, the apoptotic index was with-
out statistical differences among HepG2–wild-type, HepG2-PGS
shRNA, and HepG2-CDS shRNA cells (Figure 5A).
A Decrease in the p53-Dependent Bcl-xL and Bcl-2
Mitochondrial Distribution Facilitated Proapoptotic Status
The antiapoptotic Bcl-family members, Bcl-xL and Bcl-2, protein ex-
pression, andmitochondrial distributionwere investigated. In Figure 5B,
theMMC treatment was 5 μg/ml (low dose) and 20 μg/ml (high dose).
In the 5 μg/ml MMC treatment for 6 hours, the Bcl-xL and Bcl-2 ex-
pression in whole lysate remained unaffected compared with control
(Figure 5,B andC ), whereas the increase in Bcl-xL and Bcl-2mitochon-
drial distribution was found in their mitochondrial lysate (Figure 5, B
and D). In HepG2–CDS-2 shRNA cells, as a limitation of mitochon-
drial p53 translocation, the mitochondrial distribution of Bcl-xL and
Bcl-2 was diminished compared with HepG2–wild-type cell (Fig-
ure 5D), suggesting that the result was p53-dependent. But, in the
20 μg/ml MMC treatment, the Bcl-xL and Bcl-2 expression decreased
obviously in the whole lysate (Figure 5, B and C ). The decrease of
Bcl-xL and Bcl-2 in cytosolic pool resulted in a reduction in their
mitochondrial distribution, both in HepG2–wild-type and HepG2–
CDS-2 shRNA cells (Figure 5D). The proapoptotic Bax protein expres-
sion was induced, which correlated with p53 accumulation, in both
HepG2–wild-type and HepG2–CDS-2 shRNA whole cell lysates,
and resulted in the increase of Bax protein in their mitochondrial frac-
tions (Figure 5B). We thought the apoptotic enhancement in low-dose
MMC-treated HepG2–CDS-2 shRNA cell might result from the limi-
tation of mitochondrial p53 translocation and p53-dependent Bcl-xL
and Bcl-2 mitochondrial distribution. But, in the high-dose MMC
treatment, no apoptotic enhancement observed in HepG2–CDS-2
shRNA cell might result from the decrease in both Bcl-xL and Bcl-2
expression in cytosolic pool and in the p53-dependent Bcl-xL and
Bcl-2 mitochondrial distribution.
p53 Protein Is a Crucial Factor in Bcl-xL and Bcl-2
Mitochondrial Distribution
To investigate the requirement of p53 for Bcl-xL and Bcl-2 mito-
chondrial distribution, stable clones of HEK 293T cells expressing
PGS shRNA and CDS-2 shRNA were selected (Figure 6A). Wild-type
293T cells showed a higher basal level of cytosolic p53 protein com-
pared with HepG2 cells. The addition of MMC did not increase cyto-
solic p53 protein accumulation in wild-type 293T and 293T stable
clones, suggesting the saturation state of p53 content in their cytosol
(Figure 6B). In 293Tmodels, the mitochondrial p53 level was signifi-
cantly reduced in 293T–CDS-2 shRNA and PGS shRNA-transfected
293T (293T-PGS shRNA) cells in relation to wild-type 293T (Fig-
ure 6C). In both 293T–CDS-2 shRNA and 293T-PGS shRNA cells,
the Bcl-xL and Bcl-2 expressions were without significant changes in
whole lysates, but the Bcl-xL and Bcl-2 mitochondrial distribution was
obviously reduced (Figure 6, C and D). These results showed that dis-
ruption of cardiolipin biosynthesis in 293Tmodels not only diminished
Figure 2. Determination of the characteristics of mitochondrial p53.
(A) Alkali extraction showed that themitochondrial p53was detected
in the supernatant fraction, suggesting that mitochondrial p53
retained its soluble characteristic. The membrane-integrated Cox I
protein was detected in the pellet. (B) The 1% dodecymaltoside
detergent extraction showed thatmitochondrial p53wasmore resis-
tance than integrated Cox I protein, suggesting that bothmembrane-
bound p53 (pellet) and free soluble form p53 (supernatant) coexisted
in the mitochondria. (C) The association between p53 and phospho-
lipids was evaluated by an in vitro lipid-binding assay. p53 displayed
strong lipid-binding properties with anionic phospholipids including
phosphatidylserine, cardiolipin, phosphatidylglycerol, and phospha-
tidic acid. (D) The p53 C-terminal domain and R175Hmutant showed
strong cardiolipin-binding activities. The p53 fragment containing
100 to 318 polypeptides showed mild cardiolipin-binding activity.
The N-terminal domain was irrelevant to p53-cardiolipin interactions.
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the content of mitochondrial p53 translocation but also reduced Bcl-xL
and Bcl-2 translocation to the mitochondria.
To exclude the interferences form different expression levels of
Bcl-xL and Bcl-2 among 293T models, the “Bcl-2mitochondria/whole”
and “Bcl-xLmitochondria/whole” ratios were calculated. The higher ratio
reflected the higher Bcl-xL and Bcl-2 partition to mitochondria rather
than to the cytosolic fraction. The Bcl-2mitochondria/whole and Bcl-xL
mitochondria/whole ratio significantly decreased in 293T–CDS-2 shRNA
Figure 3. Down-regulation of PGS expression decreased cellular p53 translocation tomitochondria. (A) The PGS shRNA constructs (1-5 μg of
plasmids/6-cm transfection)were transfected into theHepG2 cell for 24 hours as described inMaterials andMethods.Western blots showed
that PGS protein expression was downregulated. (B) Nontransfected control, vector control, and PGS shRNA-transfected cells were treated
5 μg/ml MMC for 12 hours, then total lysates were collected and analyzed by Western blots. The blots showed that both p53 and PGS
were induced by MMC treatments. The mitochondria fraction was isolated as described in Materials and Methods. The contents of p53
translocated to the mitochondrial fraction showed no significant difference among nontransfected control, vector control, and PGS
shRNA-transfected cells. The contents of mitochondrial p53 translocation were analyzed by densitometry. *P < .05, **P < .01, and
***P < .001, indicate a significant difference with the control. #P < .05, ##P < .01, and ###P < .001, indicate a significant difference with
theMMC-treated control. (C) The p53 transactivation inhibitor, pifithrin-α (20μM),waspretreatedandcoincubatedwith 5 to10μg/mlMMC for
24 hours. Pifithrin-α inhibited p53-responsiveMdm2and PGS induction butwas irrelevant to p53 accumulation. (D) To determine the effect of
pifithrin-α treatment on p53 mitochondrial translocation, HepG2 was pretreated with pifithrin-α for 30 minutes, followed by MMC treatment
for 12 hours. The blots showed that both p53 levels in whole and in mitochondrial lysates remained unaffected by pifithrin-α. (E) The non-
transfected control andPGSshRNA-transfected cellswith orwithout pifithrin-α (20μM)pretreatmentwere treated 5μg/mlMMC for 12hours,
then total lysates were collected and analyzed by Western blots. The blots showed that PGS expression was blocked in PGS shRNA-
transfected cells with pifithrin-α pretreatments. The contents of p53 translocated to the mitochondrial fraction significantly decreased in
PGS shRNA-transfected cellswith pifithrin-α pretreatments. The contents ofmitochondrial p53 translocationwere analyzed by densitometry.
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and 293T-PGS shRNA cells compared with wild-type 293T (Figure 6
E and F ).
The wild-type, CDS-2 shRNA-, and PGS shRNA-expressing
stable clones were also established in p53-null H1299 cells. In H1299
models, both the Bcl-2mitochondria/whole and Bcl-xLmitochondria/whole ratios
were strongly reduced in relation to the 293Tmodels with saturated p53
expression. However, the Bcl-2mitochondria/whole and Bcl-xLmitochondria/
whole ratios did not statistically differ among H1299 models (Figure 6,
E and F ). Interestingly, in both 293Tand H1299 models, the decrease
in Bcl-xLmitochondria /whole ratio was more obvious than that in the
Bcl-2mitochondria/whole ratio, suggesting that the mitochondrial partition
of Bcl-xLwas more dependent onmitochondrial p53 translocation. The
elevation of Bcl-xLmitochondria/whole ratio was found in H1299 models
expressing pCEP4-p53wt (P < .05), suggesting that p53 acts as a carrier
in the transportation of Bcl-xL to mitochondria directly. Moreover, the
Bcl-xLmitochondria/whole ratio of H1299–CDS-2 shRNA was lower than
H1299–wild-type and showed statistical significance.
Discussion
In past studies, the p53was identified as a soluble nuclear protein. Three
potential nuclear leading sequences (NLSs) and a leucine-rich nuclear
export signal that are clustered in C-terminal region are required for
p53 entry and retention in the nucleus [25]. Marchenko et al. [8] first
demonstrated that death signals can induce p53 translocation to the
mitochondria. In the present studies, we found that both membrane-
bound p53 and the soluble form of p53 coexisted in the mitochondrial
extract. The extraction discrepancies between bicarbonate and detergent
might be due to an effect on the charge of p53, as well as the ionic effects.
Moreover, a strong interaction between p53 and cardiolipin, a mito-
chondrion-restricted phospholipid, was also evidenced by an in vitro
lipid-binding assay (Figure 2). Cardiolipin is strongly partitioned at con-
tact sites and may interact with mitochondrial proteins through their
positively charged signal sequences of precursor proteins [15,16]. Cyto-
chrome c is one of the soluble basic proteins that resided in the mito-
chondrial inner membranes and was established to specifically bind to
cardiolipin [26]. The binding of cytochrome c to cardiolipin results
from electrostatic ion-ion interactions with positively charged lysine re-
sidues and negatively charged phosphate groups of cardiolipin or by a
tightly hydrophobic interaction [21]. The peroxidation of cardiolipin
disrupts binding and releases cytochrome c into the cytosol [26–28].
The nuclear homing domain usually consists of a basic amino acid core
that may be the putative cardiolipin-binding region. Three potential
NLSs are clustered at the C-terminal region of p53: NLS I (313-322,
PPQKKKPLDG), NLS II (366-369, KTKK), and NLS III (375-380,
SHRKKTM). All three NLSs are enriched in the positively charged
lysine residues and are predicted to be an electrostatic center [29–31].
The prediction was demonstrated by the potential of different p53-GST
fusion protein fragments to interact with cardiolipin. Compared with
full-length p53, the p53 polypeptides 319-393 (with NLS II and III)
and 101-318 (with a partial NLS I) showed 75% and 25% cardiolipin-
binding abilities, respectively (Figure 2). These findings suggest that
the C-terminal of p53 is the major region required for p53-cardiolipin
interaction. Cardiolipin is a main component of the mitochondrial
inner membrane. However, Marchenko et al. [8] previously reported
that p53 predominantly localizes to the surface of the mitochondria.
The apparent discrepancy may be explained by the electrostatic ion-
ion interactions between p53 and other anionic phospholipids, including
phosphatidylglycerol and phosphatidic acid. Both phosphatidylglycerol
and phosphatidic acid are precursors of cardiolipin. Moreover, the inter-
action to phosphatidic acidwasmore convincing than that to cardiolipin,
suggesting the involvement of p53 protein in earlier de novo cardio-
lipin biosynthesis pathway. The p53-phospholipids interaction might
contribute to the p53’s translocation to the mitochondria during car-
diolipin biosynthesis.
The classicmethod ofmitochondrial protein importation requires the
mitochondrial leading signal peptides and the recognition of the Tom
complex [32]. In a recent study, mutant p53 with an aberrant confor-
mation was translocated to the mitochondria through protein-protein
interactions with a chaperon system, such as hsp70 [13], hsp90, and
cochaperones [14]. Translocation of p53 to the mitochondria through
its binding to cardiolipin may be a potential mechanism. The Bid pro-
tein also showed cardiolipin-, phosphatidylglycerol-, and phospha-
tidic acid–binding activities. Bid-phospholipid interactions facilitate
Bid translocation to the mitochondria and result in cytochrome c release
Figure 4. Down-regulation of CLS (CDS-2) expression decreased
cellular p53 translocation to the mitochondria. (A) The CDS-2 shRNA
constructs (1-5 μg of plasmids/6-cm transfection) were transfected
into HepG2 cell for 24 hours as described in Materials andMethods.
Western blots showed that the CDS-2 protein expressionwas down-
regulated. (B)Nontransfected control, vector control, andCDS-2 shRNA-
transfected cells were treated 5 μg/ml MMC for 12 hours, then total
lysates were collected and analyzed by Western blots. The blots
showed p53 was induced by MMC treatments. After 5 μg/ml MMC
treatment for 12 hours, the mitochondria fraction was isolated as
described in Materials and Methods. The contents of p53 trans-
location to the mitochondrial fraction significantly decreased in CDS-2
shRNA-transfected cells. The contents of mitochondrial p53 trans-
location were analyzed by densitometry. *P < .05, **P < .01, and
***P < .001, indicate a statistical difference with the control. #P <
.05, ##P < .01, and ###P < .001, indicate a significant difference
with the MMC-treated control.
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[33–35]. The mitochondrial translocation model of Bid and p53
through cardiolipin transfer activity provides an interesting and novel
mitochondrial protein importation pathway. De novo cardiolipin bio-
synthesis occurs in three enzymatic steps, including CDS, PGS, and
CLS. The CLS protein depletion might cause a lethal effect [36,37].
In the present studies, RNA interference by the PGS and CDS-2
shRNA constructs was used to suppress endogenous PGS and CDS-2
expressions. Disruption of cardiolipin biosynthesis diminished the con-
tent of mitochondrial p53 translocation (Figures 3 and 4). Our data re-
vealed that cardiolipin and its precursors might function as a carrier and
facilitate p53 transfer to mitochondria (Figure W3).
Aside from p53 mitochondrial translocation, a p53-dependent trans-
location of antiapoptotic Bcl-xL and Bcl-2 to the mitochondria has also
been found [36–38]. A coimmunoprecipitation study showed that p53
and the Bcl-xL/Bcl-2 complex were colocalized [36]. On the basis of
our study, the p53-dependent Bcl-xL and Bcl-2 mitochondrial trans-
location was also determined by their content in cytosolic pool. The
changes of Bcl-xL and Bcl-2 level in the whole lysate resulted in increas-
ing (low-dose MMC treatment) or decreasing (high-dose MMC treat-
ment) mitochondrial translocation. In HEK 293T–CDS-2 shRNA
cell, the mitochondrial distribution of Bcl-xL and Bcl-2 was reduced
compared with wild type. Furthermore, Bcl-xL and Bcl-2mitochondrial
partition was strongly reduced in p53-null H1299 models and was
rescued in H1299 models with pCEP4-p53wt expression (Figure 6).
We thought the mitochondrial distribution of Bcl-xL and Bcl-2 is regu-
lated by mitochondrial p53 translocation (Figure W3). Also, we found
Figure 5. Decreasemitochondrial p53 content and p53-dependentBcl-xL orBcl-2mitochondrial partition enhancedMMC-induced cell death.
(A) Cells were prepared and treated with MMC for 24 hours. Pretreatment with 20 μM pifithrin-α was carried out for 30 minutes before
MMC incubation. The apoptotic indexwas analyzed by propidium iodide staining and flow cytometry as described inMaterials andMethods.
***P < .001, indicates a statistical difference with the control. #P < .05, ##P < .01, and ###P < .001, indicate a statistical difference with
MMC-treated groups. (B) The expression of p53, Bax, Bcl-xL, and Bcl-2 and their mitochondrial distributions were analyzed in MMC-treated
HepG2–wild-type and HepG2–CDS-2 shRNA cells. Both cell types were incubated with 5 and 20 μg/ml MMC for 6 hours. Low-dose (5 μg/ml)
MMC treatment did not change Bcl-xL and Bcl-2 protein expressions in either HepG2–wild-type or HepG2–CDS-2 shRNA cells. However, as
a limitation of mitochondrial p53 translocation, 5 μg/ml MMC treatment decreased Bcl-xL and Bcl-2 mitochondrial distributions in HepG2–
CDS-2 shRNA cells. High-dose (20 μg/ml) MMC treatment strongly decreased Bcl-xL and Bcl-2 protein expressions in both HepG2–wild-type
and HepG2–CDS-2 shRNA cells, resulting in the decrease in their mitochondrial distribution. (C and D) The Bcl-xL and Bcl-2 expression level
in whole lysate (C) and their mitochondrial distributions (D) were analyzed by densitometry. *P < .05, **P < .01, ***P < .001, indicate a
statistical difference with the control. #P < .05, indicates a statistical difference with MMC-treated groups.
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Figure 6. The expression and mitochondrial distribution of Bcl family members in HEK 293T cell stable clones expressing CDS-2 shRNA
and PGS shRNA. (A) The CDS-2 shRNA- and PGS shRNA-expressing stable clone was selected in HEK 293T cells. (B) HEK 293T models
have a higher p53 protein basal level. With the addition of 20 μg/ml MMC, the p53 protein content was not upregulated in 293T–wild-type,
293T–CDS-2 shRNA, and 293T-PGS shRNA cells, suggesting that the p53 status was saturated in the HEK 293T models. (C) The mito-
chondrial distributions of p53, Bcl-2, and Bcl-xL were analyzed in 293T cell models. The mitochondrial distribution of Bcl-2 and Bcl-xL was
reduced in 293T–CDS-2 shRNA and 293T-PGS shRNA cells in relation to wild-type 293T cell. (D) The Bcl-2 and Bcl-xL mitochondrial trans-
locations were analyzed by densitometry. The Bcl-2mitochondria/whole ratio (E) and Bcl-xLmitochondria/whole ratio (F) were calculated from three
HEK 293T cell models and p53-null H1299 cell models and indicate a statistical difference in relation to the wild-type control. *P < .05 and
***P < .001, indicate a statistical difference between HEK 293T models. #P < .05 and ###P < .001, indicate a statistical difference be-
tween H1299 models. aP < .05, indicates a statistical difference between H1299–wild-type control with pCEP4-p53wt expression.
158 p53 Binding with Anionic Phospholipids Li et al. Neoplasia Vol. 12, No. 2, 2010
that the change in the p53-dependent Bcl-xL mitochondrial transloca-
tion was more evident than that in the Bcl-2. It has been demonstrated
that p53 could interact with Bcl-xL directly not only by mapping bind-
ing domain analysis but also by the space-filling model [10]. It may be
the reason that Bcl-xL mitochondrial partition was blocked completely
in p53-null H1299 models (compared with HEK 293Tmodels with
saturated p53). Because the evidence for a p53/Bcl-2 interaction was de-
ficient, the p53-dependent Bcl-2 mitochondrial translocation may be
an indirect response (Bcl-xL/Bcl-2 interaction first, followed by p53
interaction with Bcl-xL). This reason can also explain why the Bcl-2
mitochondrial partition is lower than that of the Bcl-xL when p53 pro-
tein was introduced into the p53-null H1299 models.
In the nucleus, p53 functions as a transcription factor through the
DNA-binding domain (102-292) but also represses gene expres-
sion through an interaction with histone deacetylases [39]. The p53-
dependent transcription of proapoptotic products, such as Bax [5],
p53-inducible genes [4,7], BH3-only proteins Noxa [40], PUMA [41],
and p53AIP1 [42], can directly or indirectly disrupt mitochondrial in-
tegrity and cause cytochrome c release. In another pathway, the p53
protein is translocated to the mitochondria and physically interacts
with Bcl-xL [10,11], Bak [43], or manganese superoxide dismutase
[12] in the mitochondria. The in vivo significance and potential
consequences of these interactions were determined at the onset of
p53-dependent apoptosis preceding changes in redox balance, mito-
chondrial membrane potential, cytochrome c release, and caspase acti-
vation [8,12]. Emerging publications suggest that after genetic stress,
a fraction of p53 translocates into the mitochondria, inducing cyto-
chrome c release and apoptosis [8,37,44–47]. However, based on
our study, we thought mitochondrial p53 may regulate apoptosis in
a “biphasic” manner. It means that under the low-dose MMC treat-
ment, the increase in p53 and p53-dependent Bcl-xL (and Bcl-2)
mitochondrial translocation might attenuate apoptosis progression.
The prediction was proved in MMC-induced apoptotic index among
HepG2 models. In CDS-2 shRNA- and PGS shRNA-expressing cells,
the content of mitochondrial p53, Bcl-2, and Bcl-xL decreased, and
the apoptotic cell population was enhanced. We did found the cyto-
chrome c release and caspase-3 activation in MMC-treated cells in a
dose-dependent manner, but no statistical significance was found
in either the amounts of cytochrome c release or the activation of
caspase-3 between HepG2–wild-type and HepG2–CDS-2 shRNA
cells (data not shown). These data suggest that mitochondrial p53
and p53-dependent Bcl-xL (and Bcl-2) mitochondrial distribution
possess unfound functions in regulating apoptotic progression. It is
important to note the mitochondrial localization of the p53 protein
in proliferative cells [48]. Mitochondrial p53 localization in normal
conditions agrees with the recent observation of a direct positive influ-
ence of p53 onmitochondrial biogenesis and aerobic metabolism [49].
Mitochondrial p53 also exerts physical interactions with mitochondria
DNA and DNA polymerase γ and enhances error correction activities
[50]. However, the documentation of apoptotic enhancement is with-
out statistical difference in the high-dose MMC treatment. In the
high-dose condition, the mitochondrial p53 represents a pool of p53
at the outer membrane, thus after induction of apoptosis, p53 induces
outer membrane permeability and apoptosis.
In a Saccharomyces cerevisiae model, disruption of CLS (CRD1)
caused mitochondrial anion phospholipids depletion [20,51], mito-
chondrial electron transport repression [19], and apoptosis [52]. It
means that the apoptotic enhancement in our study may be because
cardiolipin is required for normal mitochondrial apoptotic regulation.
To address this issue, the mitochondrial functions, including cellular
ATP level, mitochondrial membrane potential, and cell proliferation
capacity, were evaluated in PGS shRNA- andCDS-2 shRNA-expressing
cells. Neither ATP biosynthesis nor mitochondrial membrane potential
was changed in these cells (Figure W2), suggesting that the mitochon-
drial functions remained unaffected by the transfection of CDS-2
shRNA and PGS shRNA. Also, the proliferation capacities were without
changes in these cells. In MMC-treated HepG2-PGS shRNA cell, the
pretreatment of pifithrin-α inhibited mitochondrial p53 translocation
and resulted in apoptosis enhancement.However, neithermitochondrial
p53 translocation nor apoptosis enhancement was found in the same
treatment but without pifithrin-α pretreatment (Figure 5A). Hence,
the finding of this study resulted from mitochondrial p53 content and
p53-dependent Bcl member mitochondrial distribution.
In the present study, we first found an electrostatic ion-ion inter-
action among p53 protein and cardiolipin, phosphatidylglycerol, and
phosphatidic acid. Disruption of cardiolipin biosynthesis by PGS
shRNA or CDS-2 shRNA transfection eliminated MMC-induced
mitochondrial p53 translocation, suggesting the crucial role of cardio-
lipin in the translocation of p53 to the mitochondria. Disruption of
cardiolipin biosynthesis also limited the translocation of Bcl-xL and
Bcl-2 to the mitochondria and sensitized cells in response to mild
genotoxic stimulation (Figure W3).
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MTT assay. Cells were seeded in 6-well (transiently transfected
HepG2) or 48-well (HEK 293TandH1299 stable clones with the den-
sity of 1 × 104 cells per well) plates. For HepG2 transfection, the shRNA
(1-5 μg per well) was transfected by using PolyJet in vitro DNA trans-
fection reagent (SignaGen Laboratory) for 24 hours as described in
Materials andMethods. For HEK 293Tand H1299 cell proliferation as-
say, the cell densities were determined byMTTassay after 24 to 48 hours
of incubation. Before MTT assay, the 3-(4,5-dimethyl-2-thiazolyl)-
2,5-diphenyl-2H-tetrazolium bromide (MTT) was added to each well
to achieve a final concentration of 0.04 mg/ml. After 4 hours of incu-
bation, the MTT solution was removed and replaced with 200 μl of
DMSO. Absorbance of the MTTmetabolic product, formazan, at
570 nm was measured with an ELISA reader. Reading was corrected
for the background optical density by subtracting the readings from a
blank treatment.
Cytosolic ATP content determination. Total cellular ATP level was
determined by bioluminescence using an ATP-bioluminescent assay
kit (BioVision, Mountain View, CA). Cells were lysed in lysis buffer
and centrifuged (12,000g for 5 minutes). Each reaction was performed
by mixing 5 to 10 μl of supernatant in 90 μl of reaction buffer in a
96-well plate. Finally, luciferase and luciferase substrates were added,
and luminescence intensity was counted immediately using a lumino-
meter (Berthord, Oak Ridge, TN) calibrated with the appropriate
ATP standards.
Mitochondrial membrane potential measurement. Cells were
seeded in six-well plates. Twenty-four hours after seeding, 40nMDiOC6
was added and incubated for 30 minutes at 37°C. DiOC6 is a lipophilic
fluorochrome enriched in positive charge that diffuses across the inner
membrane dependent on mitochondrial membrane potential. Finally,
cells were harvested by trypsinization and washed two to three times
by PBS. The fluorescent intensity was measured by flow cytometry with
the FL-1 filter (BD Biosciences, San Jose, CA).
Cardiolipin level determination. Cellular cardiolipin level was de-
termined by its specific fluorescent probe, 10-N -nonyl acridine orange
(NAO), and evaluated by flow cytometry or fluorescent microscopy.
Cells were harvested by trypsinization and fixed in 4% paraformalde-
hyde for 10 to 15minutes. Cell density was adjusted to 1 × 105 cells/ml
and stained with 10 μM NAO for 30 minutes at room temperature.
Stained cells were then washed twice with PBS. The NAO fluorescent
intensity was measured by flow cytometry. For fluorescent microscopy,
H1299 stable clones were seeded on cover glass. Cells were fixed in 4%
paraformaldehyde followed by NAO staining for 30 minutes. Stained
cells were then washed twice with PBS. After mounting, cells were ob-
served under a Leica fluorescent microscope.
Results
PGS shRNA and CDS-2 shRNA knockdown effects were determined
by cellular cardiolipin level. The fluorescent probe NAO that could
specifically bind to cardiolipin has been demonstrated. The NAO-
stained HepG2, HEK 293T, and H1299 cells were analyzed by fluo-
rescent microscopy or flow cytometry. The NAO fluorescent intensity
decreased approximately by 15% to 20% (transiently transfected
HepG2 models) and 40% to 50% (HEK 293T stable clone models)
compared with their wild-type cells (Figure W1, A and B). In H1299
stable clones, the NAO fluorescent intensity also decreased in PGS
shRNA-transfected H1299 cell (H1299-PGS shRNA) and H1299–
CDS-2 shRNA (compared with H1299–wild-type cell; Figure W1C ).
These data suggested that the PGS shRNA and CDS-2 shRNA do
work and decrease cardiolipin biosynthesis.
Evaluation of mitochondria function of HepG2, HEK 293T, and
H1299 models expressing PGS shRNA or CDS-2 shRNA. Cardio-
lipin depletionmay altermitochondria function.Hence, the outcome of
this studymight result frommitochondrial function changes rather than
p53 translocation. To address this issue, the mitochondrial functions,
including cellular ATP level and mitochondrial membrane potential,
were evaluated in CDS-2 shRNA-expressing cell. In ATP biosynthe-
sis, the cellular ATP contents werewithout significant differences among
wild-type, PGS shRNA-, and CDS-2 shRNA-expressing cells (both
transiently transfected HepG2 and HEK 293T stable clones) (Fig-
ure W2A). The mitochondrial membrane potentials were also without
significant differences among wild-type, PGS shRNA-, and CDS-2
shRNA-expressing cells (Figure W2B). Moreover, mitochondrial
damages often decrease cell proliferation. In HepG2, the transient
transfection of PGS shRNA and CDS shRNA did not cause the de-
crease in cell densities. In both HEK 293Tand H1299 models, their
proliferation was without statistical differences among wild-type,
CDS-2 shRNA-, and PGS shRNA-expressing cells (Figure W2C ).
These data proved that the mitochondrial functions remained unaf-
fected by the transfection of CDS-2 shRNA and PGS shRNA.
Hence, the finding of this study has high relation to the mitochon-
drial p53 content.
Figure W1. Detection of cardiolipin levels in HepG2, HEK 293T, and H1299 models by NAO staining. (A) HepG2 was transfected transiently
with CDS-2 shRNA or PGS shRNA for 24 hours by using PolyJet in vitro DNA transfection reagent (SignaGen Laboratory) as described
in Materials and Methods. (B and C) The HEK 293T and H1299 stable clones were selected by puromycin as described in Materials and
Methods. In HepG2, HEK 293T, and H1299 models, the fluorescent intensity decreased in PGS shRNA- and CDS-2 shRNA-expressing cells
compared with wild-type control. **P < .05, ***P < .001, indicate a statistical difference with the control.
Figure W2. Evaluationofmitochondria function ofHepG2,HEK293T, andH1299models expressingPGSshRNAorCDS-2 shRNA. (A) Cellular
ATP level was determined as described in SupplementaryMethods. In transiently transfected HepG2 andHEK 293T stable clones, the cellular
ATPcontentswerewithout significant differencesamongwild-type, PGSshRNA-, andCDS-2 shRNA-expressingcells. (B)Mitochondrialmem-
brane potential was determined by DiOC6 as described in Supplementary Methods. The mitochondrial membrane potentials were without
significant differences among wild-type, PGS shRNA-, and CDS-2 shRNA-expressing cells. (C) Cell density and proliferation were determined
by MTT assay as described in Supplementary Methods. In HepG2, the transient transfection of PGS shRNA or CDS-shRNA did not cause
the decrease in cell density. In HEK 293T and H1299 stable clones, the proliferation capacities were without statistical differences among
wild-type, CDS-2 shRNA-, and PGS shRNA-expressing cells.
Figure W3. Theperspectiveof p53mitochondrial translocation andp53-dependentBcl-xLmitochondrial translocation. 1. In the low-doseMMC
treatment, the activated p53 accumulated in the cytosol, whereas the expression of Bcl-xL and Bcl-2 remained unaffected. The accumulated
p53 interacted with Bcl-xL or Bcl-xL/Bcl-2 complex. However, in the high-dose MMC treatment, the expression of Bcl-xL and Bcl-2 decreased
obviously and reduced their interaction with p53. 2. The p53 interacted with phosphatidic acid and anionic phospholipids in cardiolipin bio-
synthesis pathway, after which it translocated to mitochondria by its lipid transfer ability. Diminishing cardiolipin biosynthesis pathway by
PGS shRNA and CDS-2 shRNA could eliminate p53 and p53-dependent Bcl-xL and Bcl-2 mitochondrial translocation. 3. In the low-dose MMC
treatment, the p53-dependent Bcl-xL and Bcl-2 could attenuate cell death progression. However, in the high-doseMMC treatment, only the p53
protein translocated tomitochondria. The p53 at the outer membrane could induce outer membrane permeability and promote apoptosis.
